<DOC>
	<DOCNO>NCT03015623</DOCNO>
	<brief_summary>The purpose study assess safety tolerability investigational product , SBI-101 , subject Acute Kidney Injury ( AKI ) . SBI-101 biologic/device combination product design regulate inflammation promote repair injured tissue use allogeneic human mesenchymal stromal cell . Patients randomize receive one three treatment , low dose SBI-101 , high dose SBI-101 , sham control . SBI-101 integrated renal replacement circuit patient treat 24 hour .</brief_summary>
	<brief_title>A Study Cell Therapy Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<criteria>AKI , determine Investigator base his/her clinical judgment Able tolerate indwell intravascular access Has tolerate Continuous Renal Replacement Therapy least 12 hour prior randomization Likely require Continuous Renal Replacement Therapy least additional 48 hour Ability give inform consent Female subject pregnant , plan become pregnant , lactate Known endstage liver disease Hepatorenal syndrome Acute glomerulonephritis ( e.g . rapidly progressive glomerulonephritis ; membranoproliferative glomerulonephritis ; poststreptococcal glomerulonephritis ) ; acute interstitial nephritis ( e.g . toxin drug induce interstitial nephritis ) hereditary renal disease ( e.g . Alport 's Syndrome ; polycystic kidney disease ) AKI due postrenal outflow obstruction Acute chronic vasculitis etiology At time randomization , clinical evidence ( e.g . febrile ) suggestive uncontrolled inadequately treat systemic infection History chronic systemic infection etiology regardless therapy Active malignancy ( y ) and/or receive active treatment malignancy ( y ) , exception nonmelanoma skin cancer Subjects , opinion Investigator , likely require escalate dos vasopressor attain and/or maintain hemodynamic stability History renal replacement therapy precede 2 month Systemic immunosuppressive therapy include chronic corticosteroid therapy within past 30 day Organ failure affect 2 nonrenal organ Known coagulopathy Platelet count &lt; 50,000/mL serious hematological abnormality would place subject imminent danger death Any prior medical condition , judgment Investigator , would prevent subject safely participate and/or complete study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Mesenchymal stromal cell</keyword>
	<keyword>MSC</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Mesenchymal stem cell</keyword>
</DOC>